References

Chapter 1. A Brief History of Psychiatry

Samuel H Barondes, *Better than Prozac*, Oxford Univ Press, New York, NY, 2003.

Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113:1237-1264.

Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2:632-635.

Michael J Norden, *Beyond Prozac*, ReganBooks, New York, NY, 1995.

Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522.

Siever LJ, Risch SC, Murphy DL (1981) Central cholinergic-adrenergic balance in the regulation of affective state. Psychiatry Res 5:108-109.

www.wikipedia.com

Chapter 2. My Case Study

Andy Behrman, *Electroboy*, Random House, New York, NY, 2002.

Chapter 3. General Characteristics of Brain Function

Sensory Systems

Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts, James D Watson, *Molecular Biology of the Cell, 3rd Edition*, Garland Publishing, New York, NY, 1994.

Felleman DJ, Van Essen DC (1991) Distributed hierarchical processing in the primate cerebral cortex. Cereb Cortex 1:1-47.

Information Processing

Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) Neurogenesis in the adult human hippocampus. Nature Medicine 11:1313-1317.

Gage FH (2002) Neurogenesis in the adult brain (review paper). J Neurosci 22:612-613.

Steinmetz PN, Roy A, Fitzgerald PJ, Hsiao SS, Johnson KO, Niebur E (2000) Attention modulates synchronized neuronal firing in primate somatosensory cortex. Nature 404: 187-190.

Chapter 4. Enter the Big Three

Saturation of Ser and Nore, with a Safety Factor

Bjorvatn B, Gronli J, Hamre F, Sorensen E, Fiske E, Bjorkum AA, Portas CM, Ursin R (2002) Effects of sleep deprivation on extracellular serotonin in hippocampus and frontal cortex of the rat. Neuroscience 113:323-330.

Florin SM, Kuczenski R, Segal DS (1994) Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 654:53-62.

Lena I, Parrot S, Deschaux O, Muffat-Joly S, Sauvinet V, Renaud B, Suaud-Chagny MF, Gottesmann C (2005) Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J Neurosci Res 81:891-899.

Lopez-Rodriguez F, Wilson CL, Maidment NT, Poland RE, Engel J (2003) Total sleep deprivation increases extracellular serotonin in the rat hippocampus. Neuroscience 121:523-530.

Maisonneuve IM, Keller RW, Glick SD (1990) Similar effects of D-amphetamine and cocaine on extracellular dopamine levels in medial prefrontal cortex of rats. Brain Res 535:221-226.

Moghaddam B, Bunney BS (1989) Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: comparison to amphetamine. Synapse 4:156-161.

Monti JM, Jantos H, Monti D, Alvarino F (2000) Dorsal raphe nucleus administration of 5-HT1A receptor agonist and antagonists: effect on rapid eye movement sleep in the rat. Sleep Res Online 3:29-34.

Nicolaidis S, Gerozissis K, Orosco M (2001) Variations of hypothalamic and cortical prostaglandins and monoamines reveal transitions in arousal states: microdialysis study in the rat. Rev Neurol (Paris) 157:S26-33.

Pan WH, Lai YJ, Chen NH (1995) Differential effects of chloral hydrate and pentobarbital sodium on a cocaine level and its catecholamine response in the medial prefrontal cortex: a comparison with conscious rats. J Neurochem 64:2653-2659.

Park SP (2002) In vivo microdialysis measures of extracellular norepinephrine in the rat amygdala during sleep-wakefulness. J Korean Med Sci 17:395-399.

Penalva RG, Lancel M, Flachskamm C, Reul JM, Holsboer F, Linthorst AC (2003) Effect of sleep and sleep deprivation on serotonergic neurotransmission in the hippocampus: a combined in vivo microdialysis/EEG study in rats. Eur J Neurosci 17:1896-1906.

Portas CM, Bjorvatn B, Ursin R (2000) Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol 60:13-35.

Python A, Steimer T, de Saint Hilaire Z, Mikolajewski R, Nicolaidis S (2001) Extracellular serotonin variations during vigilance states in the preoptic area of rats: a microdialysis study. Brain Res 910:49-54.

Sakai K, Crochet S (2001) Differentiation of presumed serotonergic dorsal raphe neurons in relation to behavior and wake-sleep states. Neuroscience 104:1141-1155.

Shouse MN, Staba RJ, Saquib SF, Farber PR (2000) Monoamines and sleep: microdialysis findings in pons and amygdala. Brain Res 860:181-189.

Stecker RE, Thakkar MM, Porkka-Heiskanen T, Dauphin LJ, Bjorkum AA, McCarley RW (1999) Behavioral state-related changes of extracellular serotonin concentration in the pedunculopontine tegmental nucleus: a microdialysis study in freely moving animals. Sleep Res Online 2:21-27.

Zeitzer JM, Maidment NT, Behnke EJ, Ackerson LC, Fried I, Engel J Jr, Wilson CL (2002) Ultradian sleep-cycle variation of serotonin in the human lateral ventricle. Neurology 59:1272-1274.

Dysfunction and Stress

Aston-Jones G, Rajkowski J, Kubiak P, Alexinsky T (1994) Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci 14:4467-4480.

Clayton EC, Rajkowski J, Cohen JD, Aston-Jones G (2004) Phasic activation of monkey locus ceruleus neurons by simple decisions in a forced-choice task. J Neurosci 24:9914-9920.

Dazzi L, Seu E, Cherchi G, Biggio G (2005) Chronic administration of the SSRI fluvoxamine markedly and selectively reduces the sensitivity of cortical serotonergic neurons to footshock stress. Eur Neuropsychopharmacol 15:283-290.

Dazzi L, Vignone V, Seu E, Ladu S, Vacca G, Biggio G (2002) Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142. J Psychopharmacol 16:125-131.

Hajos-Korcsok E, Robinson DD, Yu JH, Fitch CS, Walker E, Merchant KM (2003) Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats. Pharmacol Biochem Behav 74:609-616.

Jordan S, Kramer GL, Zukas PK, Petty F (1994) Previous stress increases in vivo biogenic amine response to swim stress. Neurochem Res 19:1521-1525.

Maier SF, Watkins LR (2005) Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 29:829-841.

Nakane H, Shimizu N, Hori T (1994) Stress-induced norepinephrine release in the rat prefrontal cortex measured by microdialysis. Am J Physiol 267:R1559-1566.

Petty F, Jordan S, Kramer GL, Zukas PK, Wu J (1997) Benzodiazepine prevention of swim stress-induced sensitization of cortical biogenic amines: an in vivo microdialysis study. Neurochem Res 22:1101-1104.

Usher M, Cohen JD, Servan-Schreiber D, Rajkowski J, Aston-Jones G (1999) The role of locus coeruleus in the regulation of cognitive performance. Science 283:549-554.

Walletschek H, Raab A (1982) Spontaneous activity of dorsal raphe neurons during defensive and offensive encounters in the tree-shrew. Physiol Behav 28:697-705.

Waterhouse BD, Devilbiss D, Seiple S, Markowitz R (2004) Sensorimotor-related discharge of simultaneously recorded, single neurons in the dorsal raphe nucleus of the awake, unrestrained rat. Brain Res 1000:183-191.

Zhang X, Kindel GH, Wulfert E, Hanin I (1995) Effects of immobilization stress on hippocampal monoamine release: modification by mivazerol, a new alpha 2-adrenoceptor agonist. Neuropharmacology 34:1661-1672.

Continua Versus Thresholds

Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ (1980) Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943.

Chapter 5. Big Three Strength Interactions: The Triangle

Amargos-Bosch M, Artigas F, Adell A (2005) Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 516:235-238.

Devoto P, Flore G, Longu G, Pira L, Gessa GL (2003) Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 50:200-205.

Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL (2003) Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacol (Berl) 167:79-84.

Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neurosci 84:413-429.

Page ME, Lucki I (2002) Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27:237-247.

Pan WH, Yang SY, Lin SK (2004) Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 53:44-52.

Pudovkina OL, Cremers TI, Westerink BH (2003) Regulation of the release of serotonin in the dorsal raphe nucleus by alpha1 and alpha2 adrenoceptors. Synapse 50:77-82.

Sodero AO, Valdomero A, Cuadra GR, Ramirez OA, Orsingher OA (2004) Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration. Eur J Pharmacol 503:35-42.

Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115:285-288.

Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M (2002) Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int 40:355-360.

Chapter 6. Big Three Circuits

Castren E (2005) Is mood chemistry? (review) Nat Rev Neurosci 6:241-246.

Levels of Scale

Haynes J-D, Rees G (2006) Neuroimaging: Decoding mental states from brain activity in humans. Nat Rev Neurosci 7:523-534.

Stefansson et al. (2002) Neuregulin I and susceptibility to schizophrenia. Am J Hum Genet 71:877-892.

Straub et al. (2002) Genetic variation in the 6p22.3 gene DTNBPI, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71:337-348.

Effects of Drugs

Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW (1988) Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 154:125-134.

Circuit Modulation

Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I (2004) Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 101:8186-8191.

Mood Circuits

Liotti M, Mayberg HS (2001) The role of functional neuroimaging in the neuropsychology of depression. J Clin Exp Neuropsychol 23:121-136.

Chapter 7. Big Three Functions

Sensation

Segal NL, Topolski TD, Wilson SM, Brown KW, Araki L (1995) Twin analysis of odor identification and perception. Physiol Behav 57: 605-609.

Emotion

Harmer CJ, Perrett DI, Cowen PJ, Goodwin GM (2001) Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness. Psychopharmacol (Berl) 154:383-389.

Sleep

Kayama Y, Koyama Y (2003) Control of sleep and wakefulness by brainstem monoaminergic and cholinergic neurons. Acta Neurochir Suppl 87:3-6.

Morgane PJ, Stern WC (1975) The role of serotonin and norepinephrine in sleep-waking activity. Natl Inst Drug Abuse Res Monogr Ser 3:37-61.

Reynolds CF (1987) Sleep and affective disorders. A minireview. Psychiatr Clin North Am 10:583-591.

Movement

Juhlin-Dannfelt A (1983) beta-Adrenoceptor blockade and exercise: effects on endurance and physical training. Acta Med Scand Suppl 672:49-54.

Leibowitz SF, Brown O, Tretter JR, Kirschgessner A (1985) Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus. Pharmacol Biochem Behav 23:541-550.

Seznec JC, Lepine JP, Pelissolo A (2003) Dimensional personality assessment of the members of the French junior national team of road cycling. Encephale 29:29-33.

Disease

Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118:2744-2749.

John J Ratey, Catherine Johnson, *Shadow Syndromes*, Bantam Books, New York, NY, 1998, p.20.

Vazquez SM, Mladovan AG, Perez C, Bruzzone A, Baldi A, Luthy IA (2006) Human breast cell lines exhibit functional alpha(2)-adrenoceptors. Cancer Chemother Pharmacol 58:50-61.

Gender Differences and Sexual Preference

Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, Blier P, Diksic M (1997) Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94:5308-5313.

Miscellaneous Traits

Brown GL, Linnoila MI (1990) CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry 51:31-43.

Ozawa H, Chen CS, Watanabe H, Uematsu T (1977) Effect of clonidine on blood pressure, heart rate and body temperature in conscious rats. Jpn J Pharmacol 27:47-54.

Chapter 8. The Adjustment

Skrebuhhova-Malmros T, Allikmets L, Matto V (2001) Additive effect of clonidine and fluoxetine on apomorphine-induced aggressive behavior in adult male Wistar rats. Arch Med Res 32:193-196.

Chapter 9. Effects of Drugs

Lane RM (1998) SRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 12:192-214.

Tse WS, Bond AJ (2002) Serotonergic intervention affects both social dominance and affiliative behaviour. Psychopharmacology (Berl) 161:324-330.

Ser Strengtheners

Samuel H Barondes, *Better than Prozac*, Oxford Univ Press, New York, NY, 2003, p.16.

Ser Weakeners

Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R (1999) Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 24:49-52.

Balsara JJ, Jadhav SA, Gaonkar RK, Gaikwad RV, Jadhav JH (2005) Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats. Psychopharmacol (Berl) 179:597-605.

Blackshear MA, Martin LL, Sanders-Bush E (1986) Adaptive changes in the 5-HT2 binding site after chronic administration of agonists and antagonists. Neuropharmacol 25:1267-1271.

Davis R, Whittington R, Bryson HM (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53:608-636.

Feder R (1991) Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 52:163-164.

Greenway SE, Pack AT, Greenway FL (1995) Treatment of depression with cyproheptadine. Pharmacotherapy 15:357-360.

McCormick S, Olin J, Brotman AW (1990) Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry 51:383-384.

Offord SJ, Warwick RO (1984) Ketanserin alters [3H]serotonin uptake and release in rat hypothalamus. Eur J Pharmacol 104:379-382.

Pazzagli M, Giovannini MG, Pepeu G (1999) Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol 383:249-257.

Wagstaff AJ, Ormrod D, Spencer CM (2001) Tianeptine: a review of its use in depressive disorders. CNS Drugs 15:231-259.

Nore Weakeners

Alary P, Andersson JC (1988) Clonidine: prophylactic action in rapid cycling manic-depressive psychosis. Encephale 14:119-126.

Blum I, Atsmon A (1976) The possible role of beta-adrenergic and alpha-adrenergic antagonist sensitive systems in the brain in the mechanism of psychosis. Med Hypotheses 2:104-106.

Chou JC (1991) Recent advances in treatment of acute mania. J Clin Psychopharmacol 11:3-21.

Coulin K, Simon O, Emrich HM, von Zerssen D (1982) The EEG of patients with acute manic psychoses before, during and after treatment with high doses of d-propranolol and dl-propranolol (author's transl). Arch Psychiatr Nervenkr 231:323-331.

Diacicov S, Tudorache B (1990) Clonidine treatment in manic episodes. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir 35:29-32.

Flemenbaum A (1981) The use and abuse of clonidine as a psychopharmacological tool. Prog Clin Biol Res 68:209-215.

Giannini AJ, Pascarzi GA, Loiselle RH, Price WA, Giannini MC (1986) Comparison of clonidine and lithium in the treatment of mania. Am J Psychiatry 143:1608-1609.

Gowing LR, Farrell M, Ali RL, White JM (2002) Alpha2-adrenergic agonists in opioid withdrawal. Addiction 97:49-58.

Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111-116.

Hardy MC, Lecrubier Y, Widlocher D (1986) Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry 143:1450-1453.

Hardy-Bayle MC, Lecrubier Y, Lancrenon S, Laine J, Allilaire JF, Des Lauriers A (1989) Clonidine versus a placebo trial in manic disorder. Encephale 15:523-526.

Janicak PG, Sharma RP, Easton M, Comaty JE, Davis JM (1989) A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania. Psychopharmacol Bull 25:243-245.

Jimerson DC, Post RM, Stoddard FJ, Gillin JC, Bunney WE (1980) Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients. Biol Psychiatry 15:45-57.

Johnson JM (1984) Psychiatric uses of antiadrenergic and adrenergic blocking drugs. J Nerv Ment Dis 172:123-132.

Jouvent R, Baruch P, Simon P (1986) Manic episode after propranolol withdrawal. Am J Psychiatry 143:1633.

Jouvent R, Lecrubier Y, Puech AJ, Simon P, Widlocher D (1980) Antimanic effect of clonidine. Am J Psychiatry 137:1275-1276.

Kontaxakis V, Markianos M, Markidis M, Stefanis C (1989) Clonidine in the treatment of mixed bipolar disorder. Acta Psychiatr Scand 79:108-110.

Maguire J, Singh AN (1987) Clonidine. An effective anti-manic agent? Br J Psychiatry 150:863-864.

Mateo Y, Fernandez-Pastor B, Meana JJ (2001) Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 133:1362-1370.

Moller HJ, von Zerssen D, Emrich HM, Kissling W, Cording C, Schietsch HJ, Riedel E (1979) Action of d-propranolol in manic psychoses. Arch Psychiatr Nervenkr 227:301-317.

Peet M, Yates RA (1981) Beta-blockers in the treatment of neurological and psychiatric disorders. J Clin Hosp Pharm 6:155-171.

Pudovkina OL, Kawahara Y, de Vries J, Westerink BH (2001) The release of noradrenaline in the locus coeruleus and prefrontal cortex studied with dual-probe microdialysis. Brain Res 906:38-45.

Rackensperger W, Fritsch W, Schwarz D, Stutte KH, Zerssen D (1976) The effect of the beta-adrenergic blocking agent propranolol in mania (author's transl). Arch Psychiatr Nervenkr 222:223-243.

Robson RD, Antonaccio MJ, Saelens JK, Liebman J (1978) Antagonism by mianserin and classical alpha-adrenoceptor blocking drugs of some cardiovascular and behavioral effects of clonidine. Eur J Pharmacol 47:431-442.

Saper JR, Lake AE, Cantrell DT, Winner PK, White JR (2002) Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 42:470-482.

Stoudemire A, Brown JT, Harris RT, Blessing-Feussner C, Roberts JH, Nichols JC, Houpt JL (1984) Propranolol and depression: a reevaluation based on a pilot clinical trial. Psychiatr Med 2:211-218.

Szabo B, Fritz T, Wedzony K (2001) Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex. Br J Pharmacol 134:295-304.

Tudorache B, Diacicov S (1991) The effect of clonidine in the treatment of acute mania. Rom J Neurol Psychiatry 29:209-213.

Van Gaalen M, Kawahara H, Kawahara Y, Westerink BH (1997) The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Brain Res 763:56-62.

Van Spanning HW, van Zwieten PA (1973) The interference of tricyclic antidepressants with the central hypotensive effect of clonidine. Eur J Pharmacol 24:402-404.

Zebrowska-Lupina I (1980) Presynaptic alpha-adrenoceptors and the action of tricyclic antidepressant drugs in behavioural despair in rats. Psychopharmacology (Berl) 71:169-172.

Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas JM (1984) Clonidine in the treatment of mania and mixed bipolar disorder. Am J Psychiatry 141:1617-1618.

Dop Strengtheners

Li SX, Perry KW, Wong DT (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181-190.

Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, Marchi M, Gerrard PA, Corsi M (2003) Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 345:73-76.

Mixed Drugs

Tricyclic Antidepressants

Brosen K (2004) Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59:5-12.

Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F (1994) In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18:294-297.

Maione S, Palazzo E, Pallotta M, Leyva J, Berrino L, Rossi F (1997) Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat. Psychopharmacology (Berl) 134:401-405.

Intracellular drugs

Kovacs P, Hernadi I (2002) Iontophoresis of lithium antagonizes noradrenergic action on prefrontal neurons of the rat. Brain Res 947:150-156.

Manji HK, Hsiao JK, Risby ED, Oliver J, Rudorfer MV, Potter WZ (1991) The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Arch Gen Psychiatry 48:505-512.

Chapter 10. Overt Mental Illnesses

Halliday GM (2001) A review of the neuropathology of schizophrenia. Clin Exp Pharmacol Physiol 28:64-65.

Depression

Asnis GM, McGinn LK, Sanderson WC (1995) Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 152:31-36.

Brody AL, Saxena S, Fairbanks LA, Alborzian S, Demaree HA, Maidment KM, Baxter LR Jr. (2000) Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. J Clin Psychiatry 61:349-355.

Correa H, Duval F, Claude MM, Bailey P, Tremeau F, Diep TS, Crocq MA, Castro JO, Macher JP (2001) Noradrenergic dysfunction and antidepressant treatment response. Eur Neuropsychopharmacol 11:163-168.

Joyce PR, Mulder RT, McKenzie JM, Luty SE, Cloninger CR (2004) Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety 19:180-186.

John J Ratey, Catherine Johnson, *Shadow Syndromes*, Bantam Books, New York, NY, 1998, p.82 (quote of Dr. Mark George).

Roy A, Pickar D, Linnoila M, Potter WZ (1985) Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch Gen Psychiatry 42:1181-1185.

Salomon RM, Miller HL, Delgado PL, Charney D (1993) The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol Nov;8 Suppl 2:41-6.

Scatton B, Loo H, Dennis T, Benkelfat C, Gay C, Poirier-Littre MF (1986) Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression. Psychopharmacology (Berl) 88:220-225.

Bipolar Disorder

Samuel H Barondes, *Molecules and Mental Illness*, Scientific American Library, New York, NY, 1993.

Horrigan JP, Barnhill LJ (1999) Guanfacine and secondary mania in children. J Affect Disord 54:309-314.

Jimerson DC, Nurnberger JI Jr, Post RM, Gershon ES, Kopin IJ (1981) Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry 38:1287-1290.

Joyce PR, Fergusson DM, Woollard G, Abbott RM, Horwood LJ, Upton J (1995) Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J Affect Disorder 33:233-243.

Ostrow D, Halaris A, Dysken M, DeMet E, Harrow M, Davis J (1984) State dependence of noradrenergic activity in a rapid cycling bipolar patient. J Clin Psychiatry 45:306-309.

Unnerstall JR, Fernandez I, Orensanz LM (1985) The alpha-adrenergic receptor: radiohistochemical analysis of functional characteristics and biochemical differences. Pharmacol Biochem Behav 22:859-874.

Seasonal Affective Disorder (SAD)

Avery DH, Eder DN, Bolte MA, Hellekson CJ, Dunner DL, Vitiello MV, Prinz PN (2001) Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry 50:205-216.

Goel N, Terman M, Terman JS (2003) Dimensions of temperament and bright light response in seasonal affective disorder. Psychiatry Res 119:89-97.

Rudorfer MV, Skwerer RG, Rosenthal NE (1993) Biogenic amines in seasonal affective disorder: effects of light therapy. Psychiatry Res 46:19-28.

Schizophrenia

Caroli F, Baldacci-Epinette C, Ribeyre P (1993) Antidepressant treatment of schizophrenic patients. Encephale 19 Spec No 2:393-396.

Dina C, Nemanov L, Gritsenko I, Rosolio N, Osher Y, Heresco-Levy U, Sariashvilli E, Bachner-Melman R, Zohar AH, Benjamin J, Belmaker RH, Ebstein RP (2004) Fine mapping of a region on chromosome 8p gives evidence for a QTL contributing to

individual differences in an anxiety-related personality trait: TPQ harm avoidance. Am J Med Genet B Neuropsychiatr Genet 132B:104-108.

Eccleston D, Fairbairn AF, Hassanyeh F, McClelland HA, Stephens DA (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147:623-630.

Freedman R, Kirch D, Bell J, Adler LE, Pecevich M, Pachtman E, Denver P (1982) Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand 65:35-45.

Garver DL, Steinberg JL, McDermott BE, Yao JK, Ramberg JE, Lewis S, Kingsbury SJ (1997) Etiologic heterogeneity of the psychoses: is there a dopamine psychosis? Neuropsychopharmacol 16:191-201.

Goff DC, Brotman AW, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147:492-494.

Golimbet VE, Alfimova MV, Manandian KK, Abramova LI, Kaleda VG, Mitiushina NG, Oleichik IV, Iurov IuB, Trubnikov VI (2001) Serotonin type 2a (5-HTR2A) receptor gene polymorphism and personality traits in patients with endogenous psychoses. Genetika 37:545-548.

Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Little P, Schmidt R, Kimes I (1989) Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 46:922-928.

Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369-376.

Maas JW, Miller AL, Tekell JL, Funderburg L, Silva JA, True J, Velligan D, Berman N, Bowden CL (1995) Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. J Clin Psychopharmacol 15:361-364.

Poyurovsky M, Hermesh H, Weizman A (1996) Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clin Neuropharmacol 19:305-313.

Poyurovsky M, Isakov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M, Weizman A (1999) Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14:95-100.

Reznik I, Sirota P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20:410-416.

Sayeed Khan MN, Arshad N, Ullah N (2004) Treatment outcome of schizophrenia co-morbid with obsessive-compulsive disorder. J Coll Physicians Surg Pak 14:234-236.

Sethi BB, Dube S (1983) Propranolol in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 7:89-99.

Sievers M, Sato T, Moller HJ, Bottlender R (2005) Obsessive-compulsive disorder (OCD) with psychotic symptoms and response to treatment with SRI. Pharmacopsychiatry 38:104-105.

Solomon H Snyder, *Madness and the Brain*, McGraw-Hill, New York, NY, 1975.

Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384.

Thakore JH, Berti C, Dinan TG (1996) An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 94:194-197.

Van Kammen DP, Peter JL, van Kammen WB, Rosen J, Yao JK, McAdam D, Linnoila M (1989) Clonidine treatment of schizophrenia: can we predict treatment response? Psychiatry Res 27:297-311.

Yamamoto K, Hornykiewicz O (2004) Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:913-922.

Attention Deficit Hyperactivity Disorder (ADHD)

J Raymond DePaulo, Leslie Alan Horvitz, *Understanding Depression*, Wiley, Hoboken, NJ, 2002, pp. 61-63.

Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 41:330-336.

George Isaac, *Bipolar not ADHD*, Writers Club Press, Lincoln, Nebraska, 2001.

Jimenez-Jimenez FJ, Garcia-Ruiz PJ (2001) Pharmacological options for the treatment of Tourette's disorder. Drugs 61:2207-2220.

Robertson M (2006) Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry 15:1-11.

Spencer T, Biederman J, Wilens T, Steingard R, Geist D (1993) Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32:205-210.

Anxiety

Kathol RG, Noyes R, Slymen DJ, Crowe RR, Clancy J, Kerber RE (1980) Propranolol in chronic anxiety disorders. A controlled study. Arch Gen Psychiatry. 37:1361-1365.

Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR (1987) Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry 48:355-358.

Peet M, Ali S (1986) Propranolol and atenolol in the treatment of anxiety. Int Clin Psychopharmacol 1:314-319.

Rossi S, Singer S, Shearman E, Sershen H, Lajtha A (2005) The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Neurchem Res 30: 541-558.

Sanger DJ (1988) Behavioural effects of the alpha 2-adrenoceptor antagonists idazoxan and yohimbine in rats: comparisons with amphetamine. Psychopharmacol (Berl) 96:243-249.

Singer S, Rossi S, Verzosa S, Hashim A, Lonow R, Cooper T, Sershen H, Lajtha A (2004) Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. Neurochem Res 29:1779-1792.

Soderpalm A, Blomqvist O, Soderpalm B (1995) The yohimbine-induced anticonflict effect in the rat, Part I. Involvement of noradrenergic, serotonergic and endozepinergic(?) mechanisms. J Neural Transm Gen Sect 100:175-189.

Drug and Alcohol Abuse

Andreas K, Fischer HD, Schimdt J (1983) [Effect of central effective substances on alcohol preference.] Biomed Biochim Acta 42:391-398.

Le AD, Harding S, Juzytsch W, Funk D, Shaham Y (2005) Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl) 179:366-373.

Personality Disorders

Paris J, Zweig-Frank H, Kin NM, Schwartz G, Steiger H, Nair NP (2004) Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. Psychiatry Res 121:239-252.

Impulse Control Disorders

Campbell M, Gonzalez NM, Silva RR (1992) The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 15:69-85.

Mattes JA (1986) Psychopharmacology of temper outbursts. A review. J Nerv Ment Dis 174:464-470.

Eating Disorders

Simpson SG, al-Mufti R, Andersen AE, DePaul JR (1992) Bipolar II affective disorder in eating disorder inpatients. J Nerv Ment Dis 180:719-722.

Chapter 11. Expanded Dysthymia

Peter D Kramer, *Listening to Prozac*, Viking Penguin, New York, NY, 1993, p.197.

John J Ratey, Catherine Johnson, *Shadow Syndromes*, Bantam Books, New York, NY, 1998, p.11.

Chapter 12. Personality

Cloninger's Big Three Model

Cloninger CR (1986) A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Develop 3:167-226.

Cloninger CR (1987) A systematic method for clinical description and classification of personality variants: a proposal. Arch Gen Psych 44:573-588.

De Saint Hilaire Z, Straub J, Pelissolo A (2005) Temperament and character in primary insomnia. Eur Psychiatry 20:188-192.

Gerra G, Zaimovic A, Timpano M, Zambelli U, Delsignore R, Brambilla F (2000) Neuroendocrine correlates of temperamental traits in humans. Psychoneuroendocrinology 25:479-496.

Gutierrez-Zotes JA, Bayon C, Montserrat C, Valero J, Labad A, Cloninger CR, Fernandez-Aranda F (2004) Temperament and Character Inventory Revised (TCI-R). Standardization and normative data in a general population sample. Actas Esp Psiquiatr 32:8-15.

Hennig J, Toll C, Schonlau P, Rohrmann S, Netter P (2000) Endocrine responses after d-fenfluramine and ipsapirone challenge: further support for Cloninger's tridimensional model of personality. Neuropsychobiology 41:38-47.

Mitropoulou V, Trestman RL, New AS, Flory JD, Silverman JM, Siever LJ (2003) Neurobiologic function and temperament in subjects with personality disorders. CNS Spectr 8:725-730.

Peirson AR, Heuchert JW, Thomala L, Berk M, Plein H, Cloninger CR (1999) Relationship between serotonin and the temperament and character inventory. Psychiatry Res 89:29-37.

Swann AC, Johnson BA, Cloninger CR, Chen YR (1999) Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: a preliminary study. Psychopharmacology (Berl) 143:380-384.

Weijers HG, Wiesbeck GA, Jakob F, Boning J (2001) Neuroendocrine responses to fenfluramine and its relationship to personality in alcoholism. J Neural Transm 108:1093-1105.

The Enneagram Model

Don Richard Riso, Russ Hudson, *Personality Types: Using the Enneagram for Self-Discovery*, Houghton Mifflin, New York, NY, 1996.

Chapter 13. Dominance and Leadership

Baenninger R (1968) Catechol amines and social relations in Siamese fighting fish. Anim Behav 16:442-447.

Higley JD, Suomi SJ, Linnoila M (1996) A nonhuman primate model of type II alcoholism? Part 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Alcohol Clin Exp Res 20:643-650.

Kaplan JR, Manuck SB, Fontenot MB, Mann JJ (2002) Central nervous system monoamine correlates of social dominance in cynomolgus monkeys (Macaca fascicularis). Neuropsychopharmacol 26:431-443.

Lawrence CW, Haynes JR (1970) Epinephrine and nore-epinephrine effects on social dominance behavior. Psychol Rep 27:195-198.

Malatynska E, Kostowski W (1984) The effect of antidepressant drugs on dominance behavior in rats competing for food. Pol J Pharmacol Pharm 36:531-540.

Redmond DE, Maas JW, Kling A, Dekirmenjian H (1971) Changes in primate social behavior after treatment with alpha-methyl-para-tyrosine. Psychosom Med 33:97-113.

Chapter 14. Evolution

J Raymond DePaulo, Leslie Alan Horvitz, *Understanding Depression*, Wiley, Hoboken, NJ, 2002, pp.254-258.

Jared Diamond, *Guns, Germs, and Steel: The Fates of Human Societies*, Norton, New York, NY, 1999.

Chapter 15. Genetics

Bobb et al. (2005) Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 134:67-72.

Fan JB, Sklar P (2005) Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry 10:928-938.

Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T (2004) Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a japanese population. Neuropsychobiology 50:301-304.

Lotrich FE, Pollock BG, Ferrell RE (2001) Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 1:153-164.

Norton N, Owen MJ (2005) HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 37:121-129.

Ueno S (2003) Genetic polymorphisms of serotonin and dopamine transporters in mental disorders. J Med Invest 50:25-31.

Chapter 16. The Role of Talk Therapy

Aaron T. Beck, *Cognitive Therapy and the Emotional Disorders*, Plume, New York, NY, 1979.

Brody et al. (2001) Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 58:631-640.

Viktor E Frankl, *Man's Search for Meaning: An Introduction to Logotherapy*, Beacon Press, Boston, MA, 1959.

Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstron B, Fredrikson M (2002) Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59:425-433.

Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H (2004) Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 61:34-41.

Martin SD, Martin E, Rai SS, Richardson MA, Royall R (2001) Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 58:641-648.

Stephen A Mitchell, Margaret J Black, *Freud and Beyond: A History of Modern Psychoanalytic Thought*, Basic Books, New York, NY, 1995.

Prasko et al. (2004) The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuro Endocrinol Lett 25:340-348.

Roffman JL, Marci CD, Glick DM, Dougherty DD, Rauch SL (2005) Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 35:1385-1398.

Carl Rogers, *On Becoming a Person: A Therapist's View of Psychotherapy*, Houghton Mifflin, New York, NY, 1961.

BF Skinner, *About Behaviorism*, Vintage, New York, NY, 1974.

Straube T, Glauer M, Dilger S, Mentzel HJ, Miltner WH (2006) Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 29:125-135.

Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C, Corner J (2002) Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br J Psychiatry 181:144-152.

Chapter 17. New Directions for Improving Psychiatry

Abiodun OA (2005) Role of radiology in psychiatry: a review. East Afr Med J 82:260-266.

Chugani DC, Chugani HT (2000) PET: mapping of serotonin synthesis. Adv Neurol 83:165-171.

Chugani DC, Muzik O (2000) Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab 20:2-9.

Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT (1998) Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse 28:33-43.

Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee ML, Chugani HT (1999) Increased brain serotonin synthesis in migraine. Neurology 53:1473-1479.

Dhaenen H (2001) Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosci 251 Suppl 2:II76-80.

Fu X, Tan PZ, Kula NS, Baldessarini R, Tamagnan G, Innis RB, Baldwin RM (2002) Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. J Med Chem 45:2319-2324.

Hagberg GE, Torstenson R, Marteinsdottir I, Fredrikson M, Langstrom B, Blomqvist G (2002) Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. J Cereb Blood Flow Metab 22:1352-1366.

Laakso A, Hietala J (2000) PET studies of brain monoamine transporters. Curr Pharm Des 6:1611-1623.

Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L (1996) [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci 58:PL 187-192.

Nakai A, Diksic M, Kumakura Y, D'Souza D, Kersey K (2005) The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Neurogastroenterol Motil 17:212-221.

Shoaf SE, Carson R, Hommer D, Williams W, Higley JD, Schmall B, Herscovitch P, Eckelman W, Linnoila M (1998) Brain serotonin synthesis rates in rhesus monkeys determined by [11C]alpha-methyl-L-tryptophan and positron emission tomography compared to CSF 5-hydroxyindole-3-acetic acid concentrations. Neuropsychopharmacology 19:345-353.

Smith KA, Morris JS, Friston KJ, Cowen PJ, Dolan RJ (1999) Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. Br J Psychiatry 174:525-529.

Sobrio F, Amokhtari M, Gourand F, Dhilly M, Dauphin F, Barre L (2000) Radiosynthesis of [18F]Lu29-024: a potential PET ligand for brain imaging of the serotonergic 5-HT2 receptor. Bioorg Med Chem 8:2511-2518.

Young SN, Leyton M, Benkelfat C (1999) Pet studies of serotonin synthesis in the human brain. Adv Exp Med Biol 467:11-18.

Improving the Current Theory

Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ (2004) Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 19:165-169.

Gross HA, Dunner DL, Lafleur D, Meltzer HL, Muhlbauder HL, Fieve RR (1977) Prostaglandins. A review of neurophysiology and psychiatric implications. Arch Gen Psychiatry 34:1189-1196.

Hong CJ, Lai IC, Liou LL, Tsai SJ (2004) Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. Neurosci Lett 355:6972.

Leiva DB (1990) The neurochemistry of mania: a hypothesis of etiology and rationale for treatment. Prog Neuropsychopharmacol Biol Psychiatry 14:423-429.

Paul IA, Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 1003:250-272.

Petty F, Trivedi MH, Fulton M, Rush AJ (1995) Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38:578-591.

Singh A, Potter A, Newhouse P (2004) Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs 7:1096-1103.

Wang et al. (2004) Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 13:1903-1911.

Zarate CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161:171-174.

Zarate CA, Quiroz JA, Singh JB, Denicoff KD, DeJesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430-432.

Using Existing Drugs More Effectively

Keller S, Frishman WH (2003) Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev 11:73-93.

Creating New Drugs

Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, VanderMaelen CP, Yocca FD (2003) Development of a presynaptic 5-HT1A antagonist. Bioorg Med Chem Lett 13:285-288.

The Drug Companies

Marcia Angell, *The Truth About the Drug Companies: How They Deceive Us and What to Do About It*, Random House, New York, NY, 2004.

Merrill Goozner, *The $800 Million Pill: The Truth Behind the Cost of New Drugs*, University of California Press, Berkeley, CA, 2004.

Chapter 18. Closing Thoughts

Aldous Huxley, *Brave New World*, Harper & Brothers, New York, NY, 1932.

General References

American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision; American Psychiatric Association, Washington, DC, 2000.

Samuel H Barondes, *Better than Prozac*, Oxford Univ Press, New York, NY, 2003.

Avery Z Conner, *Fevers of the Mind*, PublishAmerica, Frederick, Maryland, 2002.

Avery Z Conner, *100 Questions Psychiatry Should Face*, iUniverse, Lincoln, Nebraska, 2002.

Frederick K Goodwin, Kay R Jamison, *Manic-Depressive Illness*, Oxford Univ Press, New York, NY, 1990.

Kay R Jamison, *An Unquiet Mind*, Knopf, New York, NY, 1995.

Kay R Jamison, *Touched with Fire*, Free Press, New York, NY, 1993.

Eric R Kandel, James H Schwartz, Thomas M Jessell, *Principles of Neural Science, 4th Edition*, McGraw-Hill Medical, New York, NY, 2000.

Peter D Kramer, *Against Depression*, Viking Penguin, New York, NY, 2005.

Peter D Kramer, *Listening to Prozac*, Viking Penguin, New York, NY, 1993.

Paul R McHugh, Phillip R Slavney, *The Perspectives of Psychiatry, 2nd Edition*, The Johns Hopkins University Press, Baltimore, MD, 1998.

John Nolte, *The Human Brain*, Mosby-Year Book, St. Louis, Missouri, 1993.

Michael J Norden, *Beyond Prozac*, ReganBooks, New York, NY, 1995.